Supply of the product Adrenaline by Link Medical Products

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was introduced to regulate the supply of therapeutic goods in Australia, ensuring that these products are safe and of high quality. This legislation provides a framework for the regulation of therapeutic goods, including medicines, medical devices, and blood and blood components, by establishing controls over their importation, manufacture, supply, and advertising. The Act aims to protect public health by ensuring that therapeutic goods are safe, of acceptable quality, and that their benefits outweigh any risks. In 2013, the Therapeutic Goods Administration, under the Department of Health, granted consent for the supply of a specific adrenaline injection product by Link Medical Products that did not conform to certain labelling and information requirements specified in Therapeutic Goods Order 69, subject to specific conditions to mitigate any potential risks.

Scope and Application

The Therapeutic Goods Act 1989 is a Commonwealth Act that applies to the regulation of therapeutic goods in Australia, including medicines, medical devices, blood and blood components, and therapeutic appliances. The Act applies to all therapeutic goods supplied in Australia, regardless of the jurisdiction, and regulates the import, export, supply, and advertising of these goods. The Act applies to individuals, companies, and other entities that are involved in the supply of therapeutic goods in Australia, including manufacturers, importers, sponsors, and healthcare providers. The Act also applies to the conduct and transactions related to the supply of therapeutic goods. The Act extends its application through subordinate instruments such as regulations and standards, which provide further detail on specific aspects of the regulation of therapeutic goods. Certain therapeutic goods are excluded from the application of the Act, such as goods supplied for personal use, goods supplied for research purposes, and goods that are not intended for therapeutic use. Additionally, certain exemptions and thresholds apply to certain types of therapeutic goods, such as low-risk medical devices.

Key Provisions

The Therapeutic Goods Act 1989, as referenced in the Gazette on December 3, 2013, addresses the consent given by the delegate of the Secretary of the Department of Health for the supply of a specific medical product, adrenaline – Link (as acid tartrate) 1:10,000 1 mg/10 mL injection BP pre-filled syringe. This consent, granted under subsection 14 and 14A of the Act, allows the supply of the product by Link Medical Products Pty Ltd, despite it not conforming to the Therapeutic Goods Order (TGO) 69. The product does not meet certain standards due to issues such as missing warning statements, unspecified excipient quantities, and absence of a purpose statement or label information as required by the Order. The consent is, however, conditional and applies until the end of February 2014. It stipulates that the product must be identical to the previously approved Australian version and includes the requirement for a Dear Healthcare Provider letter to accompany the product, detailing the differences between the approved Australian and UK product information. Under the Therapeutic Goods Act 1989, the obligations imposed on Link Medical Products Pty Ltd include ensuring that any product supplied adheres to the regulatory standards set out in the Therapeutic Goods Order (TGO) 69. This involves providing adequate warning statements, specifying excipient quantities, stating the intended purpose of the product, and including the necessary label information. The company must also ensure that the product supplied is identical to the previously approved version and must distribute the Dear Healthcare Provider letter, which explains the consent's conditions and informs healthcare providers of the differences between the UK and Australian product information. Compliance with these obligations is crucial to maintain the product's eligibility for supply under the Act. In accordance with the Therapeutic Goods Act 1989, any breach of the conditions set out in the consent granted by the delegate of the Secretary may result in significant consequences. The Act provides for both civil and criminal penalties for non-compliance. For example, failure to adhere to the specified conditions of supply could lead to the product being considered as non-compliant with the Therapeutic Goods Act, potentially resulting in legal action against the company. The specific penalties for breaches can include fines and, in severe cases, criminal charges. The exact penalties are not detailed in the provided text but generally reflect the severity of the non-compliance and its potential impact on public health and safety.